The Sensex, which, scaled to a new lifetime intra-day high of 9994, tumbled into negative zone to touch a low of 9819, and finally closing with a loss of 61 points at 9,859.
After scaling to a new all-time high of 9714, the Sensex finally closed with a gain of 136 points at 9,686.
The Sensex opened with a good positive gap of 18 points at 4,075. It is now up 21 points at 4,078.
The Sensex closed with a huge loss of 1.4% (138 points) at 9,445 owing to profit taking.
Within days of announcing mega investments for building in Hyderabad its second data centre cluster in India, Amazon Web Services (AWS) on Monday said it is excited about the India market, where cloud adoption offers massive headroom for growth. Pledging its long-term commitment to the India market, AWS, Amazon's cloud computing unit, said it expects global uncertainties to accelerate the decisions by companies to opt for flexible, on-demand cloud infrastructure to pare costs, gain efficiencies and drive business innovation. "Cloud reacts well to uncertainty," Puneet Chandok, president - commercial business, AWS India and South Asia, Amazon Internet Services Pvt Ltd (AISPL) told PTI.
The Sensex opened with a positive gap of 11 points at 8,084, and dropped to a low of 8,050 in early deals.
Domestic pharma major Panacea Biotec in collaboration with Russian sovereign wealth fund Russian Direct Investment Fund (RDIF) has begun the production of 'Sputnik V' COVID-19 vaccine in India, according to a joint statement issued.
James was suspended on July 28 after the ministry launched a probe into the alleged irregularities in appointments and recruitment of faculty and compliance to reservation rosters during his tenure.
Benchmark indices Sensex and Nifty retreated from over one-week highs to close lower on Wednesday due to profit booking in banking, IT and metal stocks amid weak global trends. After a two-day rally, the 30-share BSE Sensex dropped by 90.99 points or 0.16 per cent to settle at 57,806.49 in volatile trade. As many as 19 of its constituents declined while 11 advanced. The broader Nifty slipped by 19.65 points or 0.11 per cent to close at 17,213.60 with 31 of its stocks ending in the red.
'If he has not achieved 'Congress mukt Bharat' even now, the question of his creating a 'DMK mukt Tamil Nadu' does not arise,' points out N Sathiya Moorthy.
'The correction could take two to three months and traders need to be careful.' 'For investors, this could be a good time to nibble in.'
The Sensex opened a tad higher at 5,073 - up six points, and is now at 5,081 - up 14 points.
The Sensex opened a point higher at 5,104. The index slipped into negative zone and is now at 5,077 - down 26 points. The Nifty is at 1,597 - down seven points.
The Sensex staged a smart recovery as it rallied from the day's low of 9897 to a high of 10,093 - up 2% (196 points).
Ranbaxy soared 6.5% to close at Rs 433. Cipla gained 1.6% at Rs 562. Dr.Reddy's, too, was up over 1% at Rs 1,205.
The Sensex opened on a flat note at 4,452. It is now up six points at 4,459.
The Sensex closed with a gain of 16 points at 3,780.\n\n\n\n
In a virtual conference from Moscow, Dmitriev said Sputnik V is not only 'one of the most effective' but also among the 'affordable' vaccines in the world.
Tech Mahindra was the top loser in the Sensex pack, shedding over 3 per cent, followed by NTPC, IndusInd Bank, Kotak Bank and Reliance Industries. NSE Nifty fell 185.60 points to 17,671.65.
The BSE Sensex opened 9 points higher at 5,713. Continued buying has meant that the indices have moved further upwards. The Sensex is now at 5,734, up 30 points.
The Sensex opened with a positive gap of 11 points at 5,381, it slipped marginally to touch an intra-day low of 5,380.
10 non-bank and non-finance stocks from the BSE500 Index universe that offer an optimal blend of low valuation, reasonably robust revenue and earnings growth in recent quarters, a strong balance sheet, and most importantly, positive cash flow from their operations.
Foreign portfolio investors (FPIs) who invest from Mauritius into Indian companies that dole out bonus debentures will get impacted by the tax avoidance provisions on bonus stripping. The FY23 Budget has extended these provisions - applicable only to MFs, so far - to shares and units of REITs, InvITs and AIFs. The move will especially affect large institutional investors who sell original units within nine months after the record date because the loss arising from sale of original units would have to be ignored for the purposes of computing taxable income and cannot be set off against any other capital gain.
The drug comes in powder form in a sachet, which is taken orally by dissolving it in water. It accumulates in the virus-infected cells and prevents virus growth by stopping viral synthesis and energy production.
Even smaller companies like Torrent Pharma and Alembic file five to 10 ANDAs every year.
An appreciating rupee, unabated buying by domestic institutional investors (DIIs) and encouraging earnings by blue-chips contributed to the uptrend
Concessional rate of tax on dividends received by Indian companies from foreign subsidiaries will be done away with from April 1, a change that may hamper global expansion of Indian companies and compel some firms to move their headquarters out of India to geographies such as Singapore and Dubai. At present, dividends received by Indian companies from their foreign subsidiaries are subject to a concessional tax rate of 15 per cent under Section 115BBD of the Income Tax (I-T) Act. The provisions of this section shall not apply from assessment year 2023-24 onwards, according to the Finance Bill.
The Centre told the apex court that it has fast tracked the emergency approvals for foreign produced COVID-19 vaccines that have been granted approval in other countries
Face NPPA fine for overcharging on anti-asthma drug
Reinvent and innovate will be the key mantra for the Indian pharma industry in the New Year as the 'pharmacy of the world' looks to move from volume to value leadership, amid emerging challenges of inflation and pricing pressures in the global markets. While R&D investment, market competitiveness, regulatory scrutiny, and domestic price regulations are expected to shape the growth of generics and injectable products, concerns such as price control and customs duties on medical equipment will continue to bother the healthcare industry in 2023. The industry believes that in view of India's G20 Presidency, digital health innovation, achieving universal health coverage, improving healthcare infrastructure and delivery will continue to be the key driving factors in 2023.
Late selling in blue-chips like Reliance Industries, ITC, Infosys, TCS and Bharti Airtel dragged down the index from the record level to close flat.
Better-than-expected financial results in Q3 due to higher revenue growth and margins in key markets fuel the rally
Health Minister Harsh Vardhan said the COVID-19 vaccine will be available in the next few months and it is estimated that by July-August 400-500 million doses will be made available for 25-30 crore people.
147 domestic and international recruiters -- including Ola, Amazon, Flipkart and Xiaomi -- hired all 460 graduates.
Some of our leaders were busybusy over the weekend.
The official expressed hope on the success of the five vaccines that are under different phases of trial in the country.
Titan was the top gainer in the Sensex pack, rising over 3 per cent, followed by M&M, Reliance Industries, Axis Bank, TCS, Maruti and Infosys. NSE Nifty surged 122.10 points to 15,885.15.
ONGC was the top loser in the Sensex pack, shedding around 5 per cent, followed by SBI, Axis Bank, ICICI Bank, Bajaj Auto and Maruti. On the other hand, IndusInd Bank, HUL, Dr Reddy's, NTPC and Reliance Industries were among the gainers.
